GO:0140261 BCOR complex: Epigenetic Repression, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140261 (BCOR complex) is a biological process term describing the activity of the noncanonical Polycomb Repressive Complex 1.1 (PRC1.1), in which BCOR acts as a core subunit that recruits the complex to chromatin and modulates gene repression.
• The BCOR complex is best known for its role in hematopoietic stem cell maintenance and its frequent mutation in acute myeloid leukemia (AML) and other cancers.
• BCOR loss or mutation is associated with specific AML ontogeny, including secondary AML and AML with myelodysplasia-related changes.
• Beyond cancer, the BCOR complex regulates developmental processes such as syncytiotrophoblast differentiation and bone remodeling, and its disruption can accelerate SHH-driven medulloblastoma.
• BCOR complex components are emerging as modulators of epigenetic therapy response, including menin inhibitor sensitivity in AML.
• Experimental models for studying the BCOR complex include CRISPR knockout, point mutation, knock-in, and overexpression cell systems, as well as CRISPR library screening and bioinformatics analysis.
Description
The BCOR complex (GO:0140261) is a biological process term that encompasses the assembly and function of a noncanonical Polycomb Repressive Complex 1.1 (PRC1.1) variant, in which the BCL6 corepressor (BCOR) serves as a critical scaffolding subunit. This complex is essential for epigenetic gene silencing during development and tissue homeostasis, and its dysregulation is increasingly recognized as a driver of hematological malignancies and solid tumors. Understanding the BCOR complex is therefore of high interest to researchers in epigenetics, cancer biology, and developmental biology. BCOR was initially identified as a corepressor of BCL6 and later found to be a recurrently mutated gene in acute myeloid leukemia (AML) and other cancers. The BCOR complex operates within the broader Polycomb repressive system, but unlike canonical PRC1, it utilizes a distinct set of subunits, including PCGF1, KDM2B, and SKP1, to recognize unmethylated CpG islands and deposit repressive histone marks. This unique composition allows the BCOR complex to regulate a specific subset of developmental and oncogenic genes. Recent studies have highlighted the BCOR complex as a modulator of therapeutic response, particularly in AML, where mutations in BCOR and other epigenetic regulators influence sensitivity to menin inhibitors and other targeted therapies. Moreover, the BCOR complex has been implicated in non-hematological contexts, such as bone remodeling and trophoblast differentiation, underscoring its broad biological significance. This article synthesizes current knowledge on the BCOR complex, its key genes, regulatory mechanisms, disease associations, and experimental models for research.
BCOR complex At A Glance
| GO ID | GO:0140261 |
|---|---|
| GO term | BCOR complex |
| Ontology | Biological process |
| Synonym | None listed in QuickGO |
| Major function | Epigenetic transcriptional repression via noncanonical PRC1.1 |
| Core subunit | BCOR (BCL6 corepressor) |
| Associated complex | Polycomb Repressive Complex 1.1 (PRC1.1) |
| Disease relevance | Acute myeloid leukemia, medulloblastoma, bone disorders, developmental defects |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, library screening, bioinformatics |
What Is GO:0140261?
The BCOR complex (GO:0140261) is defined as a biological process involving the activity of a Polycomb Repressive Complex 1.1 (PRC1.1) variant that contains BCOR as a core subunit. This complex mediates transcriptional repression through chromatin modification and is essential for regulating gene expression programs in development and disease.
Why Is BCOR complex Important in Cell Biology?
The BCOR complex is important because it represents a key epigenetic regulatory node that controls stem cell maintenance, differentiation, and oncogenesis. Mutations in BCOR and other complex components are recurrent in AML and other cancers, and they influence disease ontogeny and therapeutic response. Understanding the BCOR complex provides insights into fundamental chromatin biology and offers potential targets for epigenetic therapies.
• BCOR is recurrently mutated in acute myeloid leukemia, particularly in secondary AML and AML with myelodysplasia-related changes.
• The BCOR complex regulates hematopoietic stem cell self-renewal and differentiation.
• Loss of BCOR accelerates SHH-driven medulloblastoma formation in mouse models.
• BCOR complex components modulate sensitivity to menin inhibitors in AML.
• The complex is involved in bone remodeling, with targeted disruption enhancing bone formation.
• BCOR promotes syncytiotrophoblast differentiation in mice and humans.
• BCOR mutations are associated with developmental disorders such as ventricular septal defects.
• The BCOR complex is a potential biomarker for cancer prognosis and therapy selection.
• It serves as a model for studying noncanonical Polycomb repressive mechanisms.
• CRISPR-based models enable functional dissection of BCOR complex components in diverse cell types.
What Happens During BCOR complex?
Assembly of the Noncanonical PRC1.1 Complex
In simple terms: The BCOR complex is built when BCOR and its partner proteins come together on DNA.
The BCOR complex assembles as a noncanonical PRC1.1 variant, where BCOR serves as a scaffold that interacts with PCGF1, KDM2B, SKP1, and other subunits. This assembly is directed to unmethylated CpG islands by KDM2B, allowing the complex to bind specific genomic loci. The formation of this complex is essential for its repressive function and is regulated by the availability of its components.
Recruitment to Chromatin and Target Gene Recognition
In simple terms: The complex finds and attaches to specific spots on DNA to control gene activity.
Once assembled, the BCOR complex is recruited to chromatin through KDM2B-mediated recognition of CpG islands and possibly through interactions with transcription factors such as BCL6. This recruitment is critical for targeting the complex to genes involved in differentiation and development. The specificity of recruitment determines which genes are silenced.
Histone Modification and Transcriptional Repression
In simple terms: The complex marks histones to turn genes off.
The BCOR complex mediates transcriptional repression by promoting histone H2A monoubiquitination and potentially other repressive marks, leading to chromatin compaction and gene silencing. This activity is dependent on the integrity of the complex and its enzymatic subunits. The repression of target genes is crucial for maintaining cell identity and preventing aberrant differentiation.
Regulation of Developmental and Oncogenic Programs
In simple terms: By turning genes on or off, the complex controls how cells grow and specialize.
The BCOR complex regulates a wide array of developmental and oncogenic pathways. For example, it controls genes involved in hematopoietic stem cell maintenance, and its loss leads to myeloid differentiation defects. In medulloblastoma, BCOR complex loss accelerates tumor formation, indicating a tumor-suppressive role in certain contexts. Thus, the complex acts as a critical regulator of cell fate decisions.
Key Genes Involved in GO:0140261 BCOR complex
The following genes encode core components and associated factors of the BCOR complex, each with distinct roles in its assembly, targeting, and function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCOR | Core scaffold subunit; interacts with BCL6 and other factors | Recurrently mutated in AML and other cancers; essential for complex assembly |
| PCGF1 | Ring finger protein; catalytic subunit for H2A ubiquitination | Required for PRC1.1 enzymatic activity; potential therapeutic target |
| KDM2B | CpG island-binding protein; recruits complex to chromatin | Determines target gene specificity; involved in leukemogenesis |
| SKP1 | Adaptor protein; links BCOR to ubiquitin ligase machinery | Modulates complex stability and function |
| BCL6 | Transcription factor; interacts with BCOR to repress target genes | Oncogenic role in lymphoma; BCOR-BCL6 interaction is a drug target |
| RING1 | E3 ubiquitin ligase; partners with PCGF1 | Catalytic component of PRC1.1; essential for repression |
| RNF2 | E3 ubiquitin ligase; alternative partner of PCGF1 | Contributes to H2A ubiquitination; context-dependent |
| CBX proteins | Chromobox proteins; bind H3K27me3 | May associate with noncanonical PRC1.1; roles in targeting |
| KDM2A | Paralog of KDM2B; CpG island binding | Potential redundancy with KDM2B in some contexts |
| USP7 | Deubiquitinase; stabilizes BCOR | Regulates BCOR protein levels; therapeutic target |
| FBXO11 | Ubiquitin ligase; targets BCOR for degradation | Modulates BCOR stability; mutations in cancer |
| MEN1 | Menin; interacts with epigenetic complexes | Modulates menin inhibitor response in AML |
| KMT2A | Histone methyltransferase; MLL fusion partner | Cooperates with BCOR complex in leukemia |
| RUNX1 | Transcription factor; frequently mutated in AML | Co-mutated with BCOR in AML; impacts ontogeny |
| ASXL1 | Chromatin modifier; PRC2-associated | Co-mutated with BCOR in myeloid malignancies |
| TET2 | DNA demethylase; epigenetic regulator | Co-mutated with BCOR in AML; influences therapy response |
| SRSF2 | Splicing factor; mutated in AML | Co-occurs with BCOR mutations in AML |
| STAG2 | Cohesin subunit; mutated in AML | Co-mutated with BCOR; impacts prognosis |
How Is BCOR complex Regulated?
The BCOR complex is regulated at multiple levels. Its assembly and activity depend on the availability of core subunits, which can be modulated by ubiquitination and degradation; for example, FBXO11 targets BCOR for ubiquitination, while USP7 stabilizes it. Additionally, the complex's recruitment to chromatin is influenced by KDM2B expression and the epigenetic landscape. In AML, mutations in BCOR and other epigenetic regulators can alter the complex's function and influence response to menin inhibitors. Furthermore, the BCOR complex interacts with signaling pathways such as SHH, where its loss accelerates medulloblastoma formation.
BCOR complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCOR | Acute myeloid leukemia; medulloblastoma; developmental disorders | CRISPR knockout in AML cell lines; mouse models |
| PCGF1 | Leukemia; epigenetic regulation | Knockout and point mutation in hematopoietic cells |
| KDM2B | Leukemia; CpG island targeting | Knock-in of targeting mutations; overexpression |
| BCL6 | Lymphoma; B-cell differentiation | Point mutation to disrupt BCOR interaction |
| MEN1 | AML; menin inhibitor response | Knockout and overexpression in AML cells |
BCOR Complex in Acute Myeloid Leukemia
BCOR mutations are recurrent in AML, particularly in secondary AML and AML with myelodysplasia-related changes, and they define distinct ontogeny. Functional genomic studies have identified BCOR as part of the mutational landscape of AML, contributing to disease pathogenesis. Loss of BCOR function leads to impaired hematopoietic differentiation and enhanced stem cell self-renewal, promoting leukemogenesis. Moreover, BCOR mutations can influence sensitivity to menin inhibitors, with epigenetic regulation of noncanonical menin targets modulating response.
BCOR Complex in Medulloblastoma
In SHH-driven medulloblastoma, functional loss of a noncanonical BCOR-PRC1.1 complex accelerates tumor formation, indicating a tumor-suppressive role for BCOR in this context. This highlights the context-dependent functions of the BCOR complex and its importance in cerebellar development and cancer.
BCOR Complex in Developmental Disorders and Bone Remodeling
BCOR mutations are associated with developmental defects, including ventricular septal defects, suggesting a role in cardiac development. Additionally, targeted disruption of the PRC1.1 complex enhances bone remodeling, indicating that the BCOR complex regulates osteogenesis. BCOR also promotes syncytiotrophoblast differentiation, which is critical for placental development.
From BCOR complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does BCOR loss promote leukemogenesis? | CRISPR knockout of BCOR in human AML cell lines and mouse models |
| How do BCOR point mutations affect complex assembly? | Point mutation knock-in of recurrent BCOR mutations |
| Can BCOR complex components be targeted therapeutically? | Knockout and overexpression of PCGF1 or KDM2B in cancer cells |
| What is the role of BCOR in bone remodeling? | CRISPR knockout in osteoblast precursors; in vivo bone models |
| How does BCOR regulate trophoblast differentiation? | Knockout and overexpression in trophoblast stem cells |
| Does BCOR complex modulate menin inhibitor sensitivity? | CRISPR knockout of BCOR in AML cells followed by drug treatment |
How to Study the BCOR complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotypes | Studying BCOR dependency in cancer cell lines |
| CRISPR point mutation | Effect of specific mutations | Modeling recurrent BCOR mutations in AML |
| CRISPR knock-in | Tagged protein expression and localization | Proteomic and imaging studies of BCOR complex |
| RNA-seq | Transcriptional changes | Identifying genes derepressed upon BCOR loss |
| ChIP-seq | Histone modifications and factor binding | Mapping BCOR complex occupancy and H2A ubiquitination |
| AP-MS | Protein-protein interactions | Defining BCOR complex composition |
| CRISPR library screening | Genome-wide fitness and drug synergy | Identifying modifiers of BCOR mutant phenotypes |
| Bioinformatics analysis | Mutation co-occurrence and prognosis | Analyzing patient datasets for BCOR complex alterations |
CRISPR-Based Functional Genomics
CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect the function of BCOR complex components. For example, CRISPR knockout of BCOR in AML cell lines has been used to study its role in differentiation and drug response. Point mutations can mimic recurrent patient mutations to assess their impact on complex assembly and activity. Knock-in of tagged BCOR allows for proteomic and imaging studies.
Transcriptomic and Epigenomic Profiling
RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) are used to identify target genes and epigenetic marks regulated by the BCOR complex. These methods have revealed that BCOR loss leads to derepression of differentiation genes. ATAC-seq can assess chromatin accessibility changes upon BCOR complex disruption.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry (AP-MS) has been used to define the composition of the BCOR complex and its interacting partners. Proximity labeling methods such as BioID can identify dynamic interactions in living cells. These approaches are essential for understanding how mutations affect complex integrity.
Bioinformatics and Library Screening
CRISPR library screening enables unbiased identification of genes that cooperate with BCOR mutations or modulate drug response. Computational analyses of genomic datasets, such as those from The Cancer Genome Atlas (TCGA), can reveal co-mutation patterns and prognostic significance of BCOR complex alterations.
How CRISPR Can Be Used to Study GO:0140261 BCOR complex
Knockout
CRISPR knockout of BCOR or its complex partners (e.g., PCGF1, KDM2B) is used to study loss-of-function phenotypes, including effects on cell proliferation, differentiation, and drug sensitivity. For instance, BCOR knockout in AML cells has been shown to impair differentiation and confer resistance to certain therapies. Knockout models are also valuable for validating tumor suppressor roles in vivo.
Point Mutation
Point mutation knock-in via CRISPR allows researchers to model recurrent BCOR mutations found in patients. These models help determine whether specific mutations act as loss-of-function or dominant-negative alleles and how they affect complex assembly and target gene repression. Such studies can reveal genotype-phenotype correlations and guide therapeutic strategies.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the endogenous BCOR locus enables precise tracking of protein expression, localization, and interactions. This approach is particularly useful for proteomic studies and live-cell imaging of the BCOR complex. Knock-in of reporter genes can also facilitate high-throughput screening.
Overexpression
Overexpression of wild-type or mutant BCOR, or other complex components, can be achieved via CRISPR-mediated integration of inducible cassettes. Overexpression models are used to study gain-of-function effects, such as enhanced repression of target genes or altered response to epigenetic drugs. They complement knockout studies by providing a reciprocal approach.
How EDITGENE Supports BCOR complex Research
Researchers studying BCOR complex-related genes often need to determine whether a candidate gene is causally involved in epigenetic regulation, disease pathogenesis, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise functional interrogation of the BCOR complex in any cell model.
Contact EDITGENE today to design your custom CRISPR model for BCOR complex research.
Frequently Asked Questions About BCOR complex
What is the BCOR complex?
The BCOR complex (GO:0140261) is a noncanonical Polycomb Repressive Complex 1.1 (PRC1.1) variant that contains BCOR as a core subunit and mediates epigenetic transcriptional repression.
What genes are involved in the BCOR complex?
Key genes include BCOR, PCGF1, KDM2B, SKP1, BCL6, RING1, RNF2, and CBX proteins, among others.
What diseases are associated with BCOR complex mutations?
BCOR complex mutations are linked to acute myeloid leukemia, medulloblastoma, developmental disorders, and bone remodeling defects.
How does the BCOR complex repress gene expression?
It recruits to chromatin via KDM2B, then promotes histone H2A monoubiquitination and chromatin compaction, leading to gene silencing.
What is the role of BCOR in leukemia?
BCOR mutations are recurrent in AML, particularly secondary AML, and contribute to impaired differentiation and leukemogenesis.
Can CRISPR be used to study the BCOR complex?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect BCOR complex functions in cells and animal models.
What is PRC1.1 and how does it relate to BCOR?
PRC1.1 is a noncanonical Polycomb repressive complex that contains BCOR; the BCOR complex term specifically refers to the activity of this variant.
How do BCOR mutations affect menin inhibitor response?
BCOR mutations can modulate sensitivity to menin inhibitors by altering epigenetic regulation of noncanonical menin targets.
What model systems are available for BCOR complex research?
Common models include CRISPR-engineered cell lines, mouse models, and patient-derived xenografts, as well as in vitro differentiation systems.
Where can I find validated BCOR complex antibodies?
EDITGENE does not provide antibodies, but we offer validated CRISPR cell models and bioinformatics services to support your research.
Conclusion
The BCOR complex (GO:0140261) is a critical epigenetic regulator with diverse roles in development, stem cell maintenance, and disease. Its frequent mutation in AML and other cancers underscores its importance as a therapeutic target and biomarker. Advances in CRISPR technology and functional genomics are enabling precise dissection of BCOR complex biology, paving the way for novel epigenetic therapies. EDITGENE provides comprehensive services to support these research efforts, from custom cell model generation to advanced bioinformatics.
References
- 1. Tyner JW et al.. 2018. Functional genomic landscape of acute myeloid leukaemia.. Nature 562(7728):526-531 PMID: 30333627
- 2. Xing L et al.. 2025. Targeted disruption of PRC1.1 complex enhances bone remodeling.. Nat Commun 16(1):4294 PMID: 40341537
- 3. Sadowski D et al.. 2024. Polycomb Repressive Complex 1.1 Component, BCOR, Promotes Syncytiotrophoblast Differentiation in Mice and Humans.. bioRxiv PMID: 38352412
- 4. Perrot A et al.. 2024. Human Genetics of Ventricular Septal Defect.. Adv Exp Med Biol 1441:505-534 PMID: 38884729
- 5. Astolfi A et al.. 2019. BCOR involvement in cancer.. Epigenomics 11(7):835-855 PMID: 31150281
- 6. Zhou X et al.. 2024. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia.. Blood 144(19):2018-2032 PMID: 39158067
- 7. Kutscher LM et al.. 2020. Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation.. Genes Dev 34(17-18):1161-1176 PMID: 32820036
- 8. Lindsley RC et al.. 2015. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.. Blood 125(9):1367-76 PMID: 25550361
